Group items tagged

The National Institutes of Health (NIH) seeks input on the restructuring of the NIH grant application instructions. We invite comments from any interested parties. We encourage feedback from PD/PIs, Administrative Offices, Offices of Sponsored Programs, Systems Administrators, and any other parties that rely on our application submission information.

This Notice supersedes NOT-OD-15-024 about the NIH and AHRQ requirement for use of a new biosketch format and provides some latitude in the transition for those who have already been compiling biosketches for their large grant applications with deadlines in early in 2015. NIH and AHRQ encourages applicants to use the newly published biosketch format for all grant and cooperative agreement applications submitted for due dates on or after January 25, 2015, and will require use of the new format for applications submitted for due dates on or after May 25, 2015. Applicants may submit using the new biosketch format for due dates before January 25, 2015, if they wish.

The purpose of this Notice is to inform new NIH applicants, their mentors, and grant administrators at their institution about two upcoming webinars the NIH Center for Scientific Review (CSR) is hosting in November 2015.  These webinars are designed to give participants useful insights into our application submission and peer review processes.  CSR is the portal for NIH grant applications and their review for scientific and technical merit.

PCORI seeks to fund pragmatic clinical trials, large simple trials, or large-scale observational studies that compare two or more alternatives for addressing prevention, diagnosis, treatment, or management of a disease or symptom; improving healthcare system-level approaches to managing care; communicating or disseminating research results to patients, caregivers, or clinicians; or eliminating health or healthcare disparities. Proposed studies must address critical clinical choices faced by patients, their caregivers, clinicians, or delivery systems. They must involve broadly representative patient populations and be large enough to provide precise estimates of hypothesized effectiveness differences and to support evaluation of potential differences in treatment effectiveness in patient subgroups.

(RFA-NS-19-025 is being reissued to accommodate an additional receipt date). The purpose of this funding opportunity announcement (FOA) is to invite applications for the Specialized Clinical Centers (hubs) of the Early Phase Pain Investigation Clinical Network (EPPIC-Net). EPPIC-Net will serve as the cornerstone of the NIHs Helping to End Addiction Long-term (HEAL) Initiative. EPPIC-Net will provide a robust and readily accessible infrastructure for carrying out in depth phenotyping and biomarker studies in patients with specific pain conditions, and the rapid design and performance of high-quality Phase 2 clinical trials to test promising novel therapeutics for pain from partners in academia or industry. Studies will bring intense focus to patients with well-defined pain conditions and high unmet therapeutic needs. EPPIC-Net will consist of one Clinical Coordinating Center (CCC), one Data Coordinating Center (DCC) and approximately 10 specialized clinical centers (hubs). The purpose of this funding opportunity announcement (FOA) is to invite applications for the hubs within EPPIC-Net. A hub will typically be a regional medical center that will actively enroll subjects into clinical trials and studies performed in EPPIC-Net. Each hub should have ready access to patient populations with specific pain conditions and have expertise in characterization of that pain condition. A hub will additionally provide scientific leadership and administrative oversight to its multiple (2-10) satellite sites (spokes). This FOA solicits applications EPPIC-Net Specialized Clinical Centers. Separate FOAs have been issued to solicit applications for the Clinical Coordinating Center (RFA-NS-18-036) and Data Coordinating Center (RFA-NS-18-035). Clinical trials conducted through EPPIC-Net may come from a variety of sources including the HEAL Partnership, as described above, or from separate NIH funding announcements.

This Funding Opportunity Announcement invites applications to establish NINR P30 Center of Excellence. The purpose of the NINR P30 Centers of Excellence is to support shared resources and facilities for categorical research by a number of scientists who focus on a common research problem. The core grant is integrated with the center's component projects or program projects, though funded independently from them. This support, by providing more accessible resources, is expected to assure a greater productivity than from the separate projects and program projects.

The National Heart, Lung, and Blood Institute (NHLBI) is seeking a Data Coordinating Center (DCC) for biospecimen and consent related activities for the Sudden Death in the Young (SDY) Case Registry. SDY is a tragic event with longstanding impact on families and communities. Although the causes of SDY are myriad, sudden unexpected infant death (SUID), sudden cardiac death and sudden unexpected death in epilepsy (SUDEP) are three examples that have inspired public health efforts at prevention. Yet fundamental gaps in knowledge about incidence, mechanisms, and risk factors for SDY limit the identification of effective prevention efforts. This acquisition is for one contract for a SDY Data Coordinating Center with subcontracts and/or other mechanisms as needed to accomplish all necessary work described in the Statement of Work.

The Oncology Nursing Society Foundation is seeking Letters of Intent from beginning researchers for its mentored Research Career Development Award. Through the annual program, grants of up to $20,000 will be awarded to support short-term oncology research training and mentorship, with each fellow receiving up to $18,000 to cover related expenses; the mentor (or the mentor's institution) will receive a $2,000 award in the form of an unrestricted honorarium to cover his/her consultative or research-related expenses and/or other institutional costs. To be eligible, applicants must be a registered nurse with an interest in oncology and have a completed PhD degree in nursing or a related discipline. The awards are available for beginning researchers (i.e., up to eight years after completing a PhD degree with no history of research funding as a principal investigator).

The NIH Research Evaluation and Commercialization Hub (REACH) program is envisioned as a partnership program between NIH and the qualifying research institutions to accelerate the creation of small businesses and the transition of discoveries originating from academic research into products that improve health. REACH Hubs will foster the advancement of therapeutics, preventatives, diagnostics, devices, and tools in a manner consistent with business case development, that address the needs of patients and public health.

This FOA encourages research relevant to the development of therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as "high priority" genetic conditions where screening may be possible in the near future. Demonstrating the benefits of treatment is often a primary criterion for including a condition on a newborn screening panel; therefore, this FOA, a "high priority" condition is one where screening is not currently recommended but would significantly benefit from early identification and treatment. Also listed under R03

This funding opportunity announcement (FOA) solicits research projects that seek to model the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in health, illness, recovery, and overall wellbeing. Both animal and human subjects research projects are welcome. Researchers proposing basic science experimental studies involving human participants should consider this FOAs companion for basic experimental studies with humans.

The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.

The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and protected time (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. Other ICs offer separate K01 FOAs intended to increase research workforce diversity.

The United States Agency for International Development (USAID) plans to provide up to $40 million in total USAID funding over a period of five-years. The purpose of the activity is to increase utilization of FP services through universal health coverage. It will be accomplished through: 1) strengthening capacity to more effectively train medical providers and community health workers in FP in both the public and private sectors; and, 2) focusing and expanding public sector FP information and services to high need groups such as adolescents, youth, newlyweds, and postpartum girls and women. The results this activity will achieve include: 1. Increased qualified FP workforce in public and private sectors, and 2. Increased availability of public sector FP outreach contacts and services, particularly for adolescents and youth.

The purpose of the funding opportunity announcement (FOA) is to encourage research on the etiology of depressive symptoms that occur in the context of a sudden onset acute illness. Although it is known that depressive symptoms may linger and affect functional recovery long after physical recovery from an acute insult, there is a gap in knowledge about the pathobiology that may underlie these incident depressive symptoms. A greater understanding of the etiological factors that contribute to and/or mitigate a trajectory of depressive symptoms may inform a personalized, holistic approach to managing recovery from acute illness.

The purpose of the Academic Research Enhancement Award (AREA) program is to stimulate research in educational institutions that provide baccalaureate or advanced degrees for a significant number of the Nation's research scientists, but that have not been major recipients of NIH support. AREA grants create opportunities for scientists and institutions otherwise unlikely to participate extensively in NIH research programs to contribute to the Nation's biomedical and behavioral research effort. AREA grants are intended to support small-scale research projects proposed by faculty members of eligible, domestic institutions, to expose undergraduate and/or graduate students to meritorious research projects, and to strengthen the research environment of the applicant institution.   

The LRP Impact Award mechanism is being offered for the first time in FY17. The LRP Impact Award encourages applications that support the full spectrum of research projects or ideas that specifically focus on scientific and clinical lupus issues, which, if successfully addressed, have the potential to make a major impact in lupus research. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale that is established through inferential reasoning and/or critical review and analysis of the literature. Inclusion of preliminary data is encouraged. The following are important aspects of the Impact Award: * Impact: The proposed research should impact an area of paramount importance in lupus disease. It is the responsibility of the Principal Investigator (PI) to clearly and explicitly describe the potential impacts of the proposed study on lupus and to convey its level of significance. * Research Strategy: The scientific rationale and experimental methodology should demonstrate critical understanding and in-depth analysis of lupus. Experimental strategies may be novel or may be based on strong rationale derived from a literature review. * Preliminary Data: Inclusion of preliminary data, such as unpublished data from the laboratory of the PI and/or data from published literature that are relevant to lupus and support the proposed research project, is encouraged, but not required. * Focus Areas: The proposed research must address at least one of the FY17 LRP Focus Areas. Clinical trials are not allowed under this Program Announcement.